Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits

被引:18
作者
Groll, AH
Mickiene, D
Piscitelli, SC
Walsh, TJ
机构
[1] NCI, Pediat Oncol Branch, Immunocompromised Host Sect, NIH, Bethesda, MD 20892 USA
[2] NIH, Warren G Magnuson Clin Ctr, Dept Pharm, Pharmacokinet Res Lab, Bethesda, MD 20892 USA
关键词
D O I
10.1128/AAC.44.2.408-410.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The distribution of the three currently available lipid formulations of amphotericin B (AmB) into bone marrow and fat tissue was evaluated in noninfected rabbits. Groups of four animals each received either 1 mg of AmB deoxycholate (D-AmB) per kg of body weight per day or 5 mg of AmB colloidal dispersion, AmB lipid complex, or Liposomal AmB per kg per day for seven doses. Plasma, bone marrow, fat, and liver were collected at autopsy, and AmB concentrations were determined by high-performance liquid chromatography. At the investigated dosages of 5 mg/kg/day, all AmB lipid formulations achieved at least fourfold-higher concentrations in bone marrow than did standard D-AmB at a dosage of 1 mg/kg/day, Concentrations in bone marrow were 62 to 76% of concurrent AmB concentrations in the liver. In contrast, all AmB formulations accumulated comparatively poorly in fat tissue. The results of this study show that high concentrations of AmB can be achieved in the bone marrow after administration of lipid formulations, suggesting their particular usefulness against disseminated fungal infections involving the bone marrow and against visceral leishmaniasis.
引用
收藏
页码:408 / 410
页数:3
相关论文
共 22 条
[1]   DOSE-DEPENDENT ANTIFUNGAL ACTIVITY AND NEPHROTOXICITY OF AMPHOTERICIN-B COLLOIDAL DISPERSION IN EXPERIMENTAL PULMONARY ASPERGILLOSIS [J].
ALLENDE, MC ;
LEE, JW ;
FRANCIS, P ;
GARRETT, K ;
DOLLENBERG, H ;
BERENGUER, J ;
LYMAN, CA ;
PIZZO, PA ;
WALSH, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (03) :518-522
[2]   Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (04) :684-703
[3]   Carrier effects on biological activity of amphotericin B [J].
Brajtburg, J ;
Bolard, J .
CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (04) :512-+
[4]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF AMPHOTERICIN-B IN HUMAN-SERUM [J].
BRASSINNE, C ;
LADURON, C ;
COUNE, A ;
SCULIER, JP ;
HOLLAERT, C ;
COLLETTE, N ;
MEUNIER, F .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 419 :401-407
[5]   AMPHOTERICIN-B LIPID COMPLEX THERAPY OF EXPERIMENTAL FUNGAL-INFECTIONS IN MICE [J].
CLARK, JM ;
WHITNEY, RR ;
OLSEN, SJ ;
GEORGE, RJ ;
SWERDEL, MR ;
KUNSELMAN, L ;
BONNER, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :615-621
[6]  
*COMM CAR US LAB A, 1996, GUID CAR US LAB AN
[7]   Practical guide for the treatment of leishmaniasis [J].
Davidson, RN .
DRUGS, 1998, 56 (06) :1009-1018
[8]   EFFICACY OF UNILAMELLAR LIPOSOMAL AMPHOTERICIN-B IN TREATMENT OF PULMONARY ASPERGILLOSIS IN PERSISTENTLY GRANULOCYTOPENIC RABBITS - THE POTENTIAL ROLE OF BRONCHOALVEOLAR D-MANNITOL AND SERUM GALACTOMANNAN AS MARKERS OF INFECTION [J].
FRANCIS, P ;
LEE, JW ;
HOFFMAN, A ;
PETER, J ;
FRANCESCONI, A ;
BACHER, J ;
SHELHAMER, J ;
PIZZO, PA ;
WALSH, TJ .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02) :356-368
[9]  
Groll AH, 1998, ADV PHARMACOL, V44, P343, DOI 10.1016/S1054-3589(08)60129-5
[10]  
HIEMENZ JW, 1996, CLIN INFECT DIS S2, V22, P133